Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

What Have We Learned? Best Practices In The Management of DME Part 2

By: Sophie J. Bakri, MD; Peter Kaiser, MD; Baruch D. Kuppermann, MD, PHD; Christina Y. Weng, MD, MBA

Webinar Credits: 1.5

This webinar will focus on relevant and timely discussions about treating patients with diabetic retinopathy and diabetic macular edema. The COVID-19 pandemic has resulted in additional challenges for both patients and retina specialists. The esteemed panel, chaired by Sophie Bakri, MD, will examine clinical trial data and share their expertise on treatment options during these unprecedented times, methods for implementing treatment, and the role of inflammation, among other topics.
This webinar presents the same didactic material as part one, plus new case studies and a recorded question-and-answer session.

Expiration Date: Tuesday, August 31, 2021
Release Date: August 2020

Learning Objectives

  • Identify the role of inflammation in patients with DME and DR.
  • Implement treatment regimens for patients with DME and DR.
  • Through real world and post hoc analyses, identify the drawbacks to current use of anti-VEGFs in DME.
  • Differentiate steroids in the management of DME while implementing strategies for treatment and patient outcomes.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Faculty:

Sophie J. Bakri, MD
Program Chair
Professor and Chair
Department of Ophthalmology
Mayo Clinic
Rochester, Minnesota

 

Peter K. Kaiser, MD
Chaney Family Endowed Chair of Ophthalmology Research
Cole Eye Institute
Cleveland, Ohio

 

Baruch D. Kuppermann, MD, PhD
Roger F Steinert Endowed Professor
Chair, Department of Ophthalmology
Director, Gavin Herbert Eye Institute
University of California, Irvine
Irvine, California

 

Christina Y. Weng, MD, MBA
Associate Professor of Ophthalmology
Baylor College of Medicine
Houston, Texas

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Sophie J. Bakri, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Advernum, Alimera Sciences, Allegro, Allergan, EyePoint, Kala Pharmaceuticals, Oxurion, Novartis, and Roche.  Grant/Research Support: Lowy Medical Foundation and NIH.

Peter Kaiser, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allegro Ophthalmics, Allergan, Bayer, Bausch + Lomb, Biogen Idec, Boerenger Ingelheim, Clearside Biomedical, Eyevensys, Galecto, Galimedix, iRenix, jCyte,Kanghong Biotech, Kodiak Sciences, NGM Biopharmaceuticals, Novartis, Omeros, Ophthea, Ophthotech, Oxurion, Regeneron Pharmaceuticals, RegenexBio, Retinal Sciences, Santen, SciFluor, Shire, Stealth Biotherapeutics, and Verena. Grant/Research Support: National Eye Institute, National institute of Health and Research to Prevent Blindness. Speaker’s Bureau: Allegro Ophthalmics, Clearside Biomedical, Ophthotech, Retinal Sciences and Verena.

Baruch D. Kuppermann, MD, PHD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan, Aprea, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, IVERIC bio/Ophthotech,  jCyte, Novartis, Oculis, Regeneron, Revana, Ripple Therapeutics, and Theravance Biopharma. Grants/Research Support: Alcon, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, IVERIC bio, jCyte, Novartis, and Regeneron.

Christina Y. Weng, MD, MBA, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Alimera Sciences, Allergan and Novartis.

 

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.

Pretest

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident

Video Resources

Next

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident
  • AgreeNeutralDisagree
    Identify the role of inflammation in patients with DME and DR.
    Implement treatment regimens for patients with DME and DR.
    Through real world and post hoc analyses, identify the drawbacks to current use of anti-VEGFs in DME.
    Differentiate steroids in the management of DME while implementing strategies for treatment and patient outcomes.
Back